Related Experiment Videos
A Host-Dependent Prognostic Model for Elderly Patients with Diffuse Large B-Cell Lymphoma.
Katsuhiro Miura1, Jun Konishi2, Takaaki Miyake3
1Department of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan miura.katsuhiro@nihon-u.ac.jp.
The Oncologist
|April 15, 2017
Summary
A new Age, Comorbidities, and Albumin (ACA) index helps predict outcomes for elderly patients with diffuse large B-cell lymphoma (DLBCL) receiving R-CHOP chemotherapy, guiding personalized treatment strategies.
Area of Science:
- Oncology
- Hematology
- Clinical Decision-Making
Background:
- Elderly patients with diffuse large B-cell lymphoma (DLBCL) require tailored treatment strategies.
- Standard decision-making models for R-CHOP chemotherapy in this population are lacking.
Purpose of the Study:
- To develop and validate an algorithm for stratifying adherence to R-CHOP chemotherapy in elderly DLBCL patients.
- To create a prognostic model to guide treatment decisions for older adults with DLBCL.
Main Methods:
- Retrospective analysis of clinical records from 836 elderly DLBCL patients treated with R-CHOP across 19 Japanese sites.
- Development of the Age, Comorbidities, and Albumin (ACA) index based on age, albumin levels, and Charlson Comorbidity Index.
Main Results:
- The ACA index effectively stratified 3-year overall survival rates, chemotherapy tolerability, and treatment adherence.
- Independent adverse risk factors identified were age >75 years, albumin <3.7 g/dL, and Charlson Comorbidity Index ≥3.
- The ACA index demonstrated comparable performance in both the SoLT-J and West-JHOG cohorts.
Conclusions:
- The ACA index is a valuable tool for predicting prognosis and treatment tolerability in elderly DLBCL patients.
- This model aids clinicians in personalizing R-CHOP chemotherapy regimens for older adults.
- The ACA index supports informed decision-making for optimizing care in this growing patient demographic.